Fekitari Yakananga inopa 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2

Isu tinowanzo funga nekudzidzira zvinoenderana nekuchinja kwako mamiriro, uye kukura.Isu tinovavarira kubudirira kwehupfumi hwepfungwa nemuviri pamwe nekurarama kweFactory Kungopa 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Chinangwa chedu chingave chekubatsira vatengi kuziva zvinangwa zvavo. .Isu tanga tichigadzira nhamburiko dzakanaka dzekuzadzisa iyi win-win dambudziko uye tinokugamuchirai nemoyo wese kuti munyatso kunyoresa isu.
Isu tinowanzo funga nekudzidzira zvinoenderana nekuchinja kwako mamiriro, uye kukura.Isu tinovavarira kubudirira kwevakapfuma pfungwa nemuviri pamwe nekuraramaChina 4-Dibuthylamino-2-Hydroxybenzophenone uye Bba, Kugara kwedu kuwanikwa kwezvigadzirwa zvegiredhi repamusoro uye zvigadziriso zvakabatana neakanakisa kutengesa-kutanga uye mushure mekutengesa sevhisi kunovimbisa kukwikwidza kwakasimba mumusika unowedzera wepasi rose.gamuchirai vatengi vatsva uye vekare kubva kumativi ese ehupenyu kuti tibatane nesu kune ramangwana hukama hwebhizinesi uye kubudirira pamwe chete!

2'-Methoxy-3'-nitro-biphenyl-3-carboxylic acid inoshandiswa sepakati peEltrombopag.
Eltrombopag, yakagadziridzwa naGlaxoSmithKline (GSK) kuUK uye yakazogadziriswa pamwe chete neNovartis kuSwitzerland, ndiyo yekutanga uye yakatenderwa chete mamorekuru madiki asiri peptide TPO receptor agonist munyika.Eltrombopag yakabvumidzwa neUS FDA muna 2008 kurapwa kweidiopathic thrombocytopenic purpura (ITP), uye muna 2014 kurapwa kweaplastic anemia (AA).Ndiwo zvakare mushonga wekutanga wakabvumidzwa neUS FDA kurapwa kweAA mumakore makumi matatu apfuura.
Muna Zvita 2012, US FDA yakabvumidza Eltrombopag kurapwa kwethrombocytopenia muvarwere vane chisingaperi hepatitis C (CHC), kuitira kuti varwere veHepatitis C vane hurombo husina kunaka nekuda kwekuderera kweplatelet count vanogona kutanga nekuchengetedza interferon based standard therapy yezvirwere zvechiropa.Musi waFebruary 3, 2014, GlaxoSmithKline yakazivisa kuti FDA yakapa mukana wekurapa mushonga weEltrombopag kurapwa kwehemopenia muvarwere vane yakanyanya chemicalbook aplastic anemia (SAA) vasina kupindura zvizere kune immunotherapy.Musi waNyamavhuvhu 24, 2015, US FDA yakabvumidza Eltrombopag kurapwa kwethrombocytopenia muvakuru nevana vane makore 1 uye kupfuura vane chronic immune thrombocytopenia (ITP) vasina mhinduro yakakwana kune corticosteroids, immunoglobulins kana splenectomy.Musi waJanuary4, 2018, Eltrombopag yakabvumidzwa kunyorwa muChina kurapwa kwekutanga immune thrombocytopenia (ITP).

Isu tinowanzo funga nekudzidzira zvinoenderana nekuchinja kwako mamiriro, uye kukura.Isu tinovavarira kubudirira kwehupfumi hwepfungwa nemuviri pamwe nekurarama kweFactory Kungopa 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Chinangwa chedu chingave chekubatsira vatengi kuziva zvinangwa zvavo. .Isu tanga tichigadzira nhamburiko dzakanaka dzekuzadzisa iyi win-win dambudziko uye tinokugamuchirai nemoyo wese kuti munyatso kunyoresa isu.
Factory Yakananga kupaChina 4-Dibuthylamino-2-Hydroxybenzophenone uye Bba, Kugara kwedu kuwanikwa kwezvigadzirwa zvegiredhi repamusoro uye zvigadziriso zvakabatana neakanakisa kutengesa-kutanga uye mushure mekutengesa sevhisi kunovimbisa kukwikwidza kwakasimba mumusika unowedzera wepasi rose.gamuchirai vatengi vatsva uye vekare kubva kumativi ese ehupenyu kuti tibatane nesu kune ramangwana hukama hwebhizinesi uye kubudirira pamwe chete!